EXC 001 + EXC 001 + EXC 001 + EXC 001
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Reduction in Hypertrophic Skin Scarring
Conditions
Reduction in Hypertrophic Skin Scarring
Trial Timeline
Jun 1, 2011 → Apr 16, 2012
NCT ID
NCT01346969About EXC 001 + EXC 001 + EXC 001 + EXC 001
EXC 001 + EXC 001 + EXC 001 + EXC 001 is a phase 2 stage product being developed by Pfizer for Reduction in Hypertrophic Skin Scarring. The current trial status is completed. This product is registered under clinical trial identifier NCT01346969. Target conditions include Reduction in Hypertrophic Skin Scarring.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01346969 | Phase 2 | Completed |
Competing Products
4 competing products in Reduction in Hypertrophic Skin Scarring
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Biktarvy 50Mg-200Mg-25Mg Tablet | Gilead Sciences | Approved | 84 |
| EXC 001 (currently called PF-06473871) | Pfizer | Phase 2 | 51 |
| PF-06473871 + PF-06473871 | Pfizer | Phase 2 | 51 |
| 1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3% | Omeros Corporation | Approved | 80 |